101 related articles for article (PubMed ID: 11930636)
1. [Clinical significance of the novel tumor marker CYFRA21-1 in patients with esophageal cancer].
Wang T; Zhang W; Liu Y
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1390-1. PubMed ID: 11930636
[TBL] [Abstract][Full Text] [Related]
2. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer].
Mao YS; Zhang DC; Zhao XH; Wang LJ; Qi J; Li XX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):457-60. PubMed ID: 14575569
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
Tan Y; Zhang P; Zheng C
Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
6. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
7. [Detection and clinical significance of CYFRA21-1 in serum of laryngeal carcinoma patients].
Luo R; Li G; Zhu C
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Jun; 16(6):289-91. PubMed ID: 12599782
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
[TBL] [Abstract][Full Text] [Related]
11. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
12. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.
Yi Y; Li B; Wang Z; Sun H; Gong H; Zhang Z
Biomarkers; 2009 Nov; 14(7):480-5. PubMed ID: 19863186
[TBL] [Abstract][Full Text] [Related]
13. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer.
Brockmann JG; St Nottberg H; Glodny B; Sprakel B; Senninger N
Anticancer Res; 2000; 20(6D):4899-904. PubMed ID: 11332443
[TBL] [Abstract][Full Text] [Related]
14. [Studies of serum markers in patients with interstitial pneumonia/pulmonary fibrosis complicated with collagen diseases: clinical evaluation of CYFRA21-1].
Suzuki A; Masuda T; Koito N; Suzuki T; Mita S; Matsuoka Y; Irimajiri S
Ryumachi; 1996 Dec; 36(6):837-43. PubMed ID: 9122823
[TBL] [Abstract][Full Text] [Related]
15. Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer.
Shimada H; Nabeya Y; Okazumi S; Matsubara H; Kadomatsu K; Muramatsu T; Ikematsu S; Sakuma S; Ochiai T
Oncol Rep; 2003; 10(2):411-4. PubMed ID: 12579281
[TBL] [Abstract][Full Text] [Related]
16. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
17. CYFRA 21-1 serum analysis in patients with esophageal cancer.
Brockmann JG; St Nottberg H; Glodny B; Heinecke A; Senninger NJ
Clin Cancer Res; 2000 Nov; 6(11):4249-52. PubMed ID: 11106239
[TBL] [Abstract][Full Text] [Related]
18. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
19. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
[TBL] [Abstract][Full Text] [Related]
20. Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma.
Zhu WQ; Yu JM; Sun XD; Xie P; Kong L
Biomarkers; 2010 Nov; 15(7):602-7. PubMed ID: 20726807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]